Abstract
Mutagen treatment of mouse tumor cells produces at high frequency stable tumor cell variants that are rejected by syngeneic mice. As Thierry Boon discusses here, these ‘tum-’ variants express new surface antigens that can be recognized by cytolytic T lymphocytes. Tum- variants derived from spontaneous mouse tumors for which no immunogenicity had hitherto been demonstrated induce an immune protection against the parental tumor. Finally, he poses some interesting questions for future investigations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
